Valneva SE (VALN) EBIT (2021 - 2026)
Valneva SE's (VALN) quarterly EBIT came in at $32.5 million in Q1 2026, down 37.63% year-on-year from $52.0 million in Q1 2025, and up 113.31% quarter-over-quarter from -$243.8 million in Q4 2025.
Valneva SE (VALN) EBIT (2021 - 2026) Analysis & Trends
Valneva SE has disclosed EBIT across 6 years of filings, most recently posting $32.5 million for Q1 2026.
- EBIT for Q1 2026 came in at $32.5 million, down 37.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$110.0 million (down 188.86% YoY), and the FY2025 annual result was -$95.5 million, down 770.59% from the prior year.
- EBIT came in at $32.5 million for Q1 2026 at Valneva SE, up from -$243.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $94.1 million in Q3 2022 to a low of -$243.8 million in Q4 2025.
- The 5-year median for EBIT is $32.5 million (2026), against an average of -$22.9 million.
- Across the five-year window, EBIT plunged 184.96% in 2023 and jumped 322.26% in 2024, its largest moves.
- Valneva SE's EBIT stood at -$57.5 million in 2022, then sank by 184.96% to -$163.8 million in 2023, then retreated by 13.79% to -$186.4 million in 2024, then tumbled by 30.79% to -$243.8 million in 2025, then soared by 113.31% to $32.5 million in 2026.
- The last three EBIT figures came in at $32.5 million (Q1 2026), -$243.8 million (Q4 2025), and $49.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -65.83 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 32.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.45 Mn |
| Dec 31, 2025 | -243.81 Mn |
| Sep 30, 2025 | 49.39 Mn |
| Jun 30, 2025 | 51.91 Mn |
| Mar 31, 2025 | 52.04 Mn |
| Dec 31, 2024 | -186.41 Mn |
| Sep 30, 2024 | 51.76 Mn |
| Jun 30, 2024 | 44.51 Mn |
| Mar 31, 2024 | 37.79 Mn |
| Dec 31, 2023 | -163.83 Mn |
| Sep 30, 2023 | 47.79 Mn |
| Jun 30, 2023 | -20.03 Mn |
| Mar 31, 2023 | -17.79 Mn |
| Dec 31, 2022 | -57.49 Mn |
| Sep 30, 2022 | 94.09 Mn |
| Jun 30, 2022 | -140.84 Mn |
| Mar 31, 2022 | -20.68 Mn |
| Dec 31, 2021 | 201.58 Mn |
| Sep 30, 2021 | -178.58 Mn |
| Jun 30, 2021 | -66.28 Mn |